Side-by-side · Research reference

BPC-157vsN-Acetyl Epitalon Amidate

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED9/53 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

01Mechanism of Action

Parameter

BPC-157

N-Acetyl Epitalon Amidate

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011 Sikiric 2018

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Feedback intact?

No known endogenous receptor; mechanism still under investigation

—

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

N-Acetyl Epitalon Amidate

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Not specified in candidate papers

Lower / starter dose

200 mcg / day

Conservative starter for new users.

—

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

In vitro human cell cultureKhavinson 2004 Khavinson 2003

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

Chronic treatment in aging culture

Sustained effect through late passages.

Reconstitution

Bacteriostatic water, 1–2 mL

—

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

—

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

—

Cell culture protocol

—

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

Modification stability

—

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

04Side Effects & Safety

Parameter

BPC-157

N-Acetyl Epitalon Amidate

Injection site reaction

Mild irritation (anecdotal)

—

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Long-term safety

Unknown beyond Phase 2 trial duration

—

Drug interactions

None established

—

Human safety data

—

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

Theoretical telomerase risk

—

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

In vitro observations

—

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

05Administration Protocol

Parameter

BPC-157

N-Acetyl Epitalon Amidate

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

—

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration